Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-08
2006-08-08
Andres, Janet L. (Department: 1637)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S023000, C514S002600, C514S813000, C530S300000, C530S327000
Reexamination Certificate
active
07087575
ABSTRACT:
The invention provides methods and materials for treating the effects of nicotine. In particular, the invention provides methods that involve administering a neurotensin receptor (NTR) agonist to a mammal that has been exposed to nicotine. The NTR agonist typically is administered in an amount effective to diminish or abolish the effects that nicotine has on the treated mammal. NTR agonists that can be used in methods of the invention include neurotensin (NT) polypeptide analogs such as NT69L. The invention also provides compositions containing an NTR agonist in combination with other agents used to help overcome nicotine effects such as sensitization and dependence. The compositions provided herein can be used to treat the effects of nicotine, including hyperactivity, hypothermia, respiratory distress, and hypertension.
REFERENCES:
patent: 4299838 (1981-11-01), Durlach
patent: 4331646 (1982-05-01), Delaage
patent: 4518587 (1985-05-01), Laruelle et al.
patent: 5393740 (1995-02-01), Amagaya et al.
patent: 5631265 (1997-05-01), Audia et al.
patent: 6046180 (2000-04-01), Jackson et al.
patent: 6214790 (2001-04-01), Richelson et al.
patent: 0 333 071 (1989-09-01), None
patent: WO 96/03400 (1996-02-01), None
patent: WO 97/39162 (1996-12-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 99/52539 (1999-10-01), None
Imperato et al. European Journal of Pharmacology, 1986, vol. 132, pp. 337-338.
Hurt et al. The new England Journal of Medicine, 1997, vol. 337, vol. 337(17), pp. 1195-1202.
Al-Rodhan et al., “Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem,”Brain Res., 1991, 557:227-235.
Benowitz, “Pharmacodynamics of nicotine: implications for rational treatment of nicotine addiction,”Br. J. Addiction, 1991, 86:495-499.
Bissette et al., “Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin,”Nature, 1976, 262:607-609.
Boules et al., “A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents,”Brain Res., 2000, 865:35-44.
Boules et al., “Neurotensin analog selective for hypothermia over antinociceptiom and exhibiting atypical neuroleptic-like properties,”Brain Res., 2001, 919:1-11.
Boules et al., “A novel neurotensin analog blocks cocaine-and D-amphetamine-induced hyperactivity,”Eur. J. Pharmacol., 2001, 426:73-76.
Boules et al., “Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats,”Eur. J. Pharmacol., 2001, 428:227-233.
Bowden et al., “Dopamine D1and D2receptor binding sites in brain samples from depressed suicides and controls,”Brain Res., 1997, 752:227-233.
Carraway and Leeman, “The Isolation of a New Hyprotensive Peptide, Neurotensin, from Bovine Hypothalami,”J. Biol. Chem., 248(19):6854-6861.
Clineschmidt and McGuffin, “Neurotensin Administered Intracisternally Inhibits Responsiveness of Mice to Noxious Stimuli,”Eur. J. Pharmcol., 1977, 46:395-396.
Cusack et al., “Pharmacological Studies on Novel Neurotensin Mimetics: Discovery of a Pharmacologically Unique Agent Exhibiting Concentration-Dependent Dual Effects as Antagonist and Agonist,”Mol. Pharmacol., 1993, 44:1036-1040.
Cusack et al., “Pharmacolgical and Biochemical Profiles of Unique Neurotensin 8-13 Analogs Exhibiting Species Selectivity, Stereoselectivity, and Superagonsim,”J. Biol. Chem., 1995, 270(31): 18359-18366.
Cusack et al., “Reversal of Haloperidol Induced Catalepsy in Rats by a Neurotensin Agonist,”Biol. Psychiatry, 1999, 45:88S, Abstract No. 288.
Cusack et al., “Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol,”Brain Res., Abstracts and Proceedings of the 2ndBrain Research Interactive Symposium, Miami, FL, Oct. 21-23, 1999, Abstract No. P3-22.
Cusack et al., “A Single Amino Acid of the Human and Rat Neurotensin Receptors (Subtype 1) Determining the Pharmacological Profile of a Species-Selective Neurotensin Agonist,”Biochem. Pharmacol., 2000, 60:793-801.
Cusack et al., “Analysis of binding sites and efficacy of a species-specific peptide at rat and human neurotensin receptors,” J. Peptide Res., 2000, 55:72-80.
Fauq et al., “Synthesis of (2S)-2-amino-3-(1H-4-indolyl)propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides,”Tetrahedron: Asymmetry, 1998, 9:4127-4134.
Fiore et al., “Helping Wisconsin Women Quit Smoking: A Successful Collaboration,”Wisconsin Medical Journal, Apr. 2000, 99:68-72.
Fredrickson et al., “Blockade of Nicotine-Induced Locomotor Sensitization by a Novel neurotensin Analog in Rats,”Society for Research on Nicotine and Tobacco, 8thAnnual Meeting, Feb. 20-23, 2002, Savannah, Georgia, Abstract No. RP-2.
Fredrickson et al., “Novel Neurotensin Analog Blocks Nicotine-Induced Locomotor Sensitization,”Fourth European Conference of the Society for Research on Nicotine and Tobacco—“Improving Knowledge and Treatments pf Nicotine Addiction,” Santander, Spain, Oct. 3-5, 2002, Abstract No. 58.
Fredrickson et al., “Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats,”Eur. J. Pharmacol., 2003, 458:111-118.
Griffith et al., “Induction of Brain Hypothermia by a Neurotensin Analog in Awake Rats,” AHA Stroke Meeting Poster, (Abstract only).
Hedley et al., “The Neurotensin Agonsit NT69L Reverses Dizocilpine-Induced Disruption of Prepulse Inhibition in the Rat,”Society for Neuroscience, 2002, (Abstract only).
Henningfield et al., “Cigarette Smokers Self-Administer Intravenous Nicotine,”Pharmacol. Biochem. Behav., 1983, 19:887-890.
Hertel et al., “Repeated administration of the neurotensin analogue NT69L on amphetamine-induced hyperactivity,”Eur. J. Pharmacol., 2001, 422:77-81.
Hertel et al., “Repeated adminstration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour,”Eur. J. Pharmacol., 2002, 439:107-111.
Huang and Hanson, “Differntial effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems,”Eur. J. Pharmacol., 1997, 332:15-21.
Hughes et al., “Are higher doses of nicotine replacement more effective for smoking cessation?”NicotineTobacco Research, 1999, 1:169-174.
Jolicocur and Barbeau, “Differential Neurobehavioral Effects of Neurotensin and Structural Analogues,”Peptides, 1981, 2:171-175.
Katz et al., “Neurotensin Analog NT69L Induces Rapid and Prolonged Hypothermia after Hypoxic Ischemia,”Academic Emergency Medicine, 2001, 8(12):1115-1121.
Kilts et al., “Simultaneous Quantification of Dopamine, 5-Hydroxytryptamine and Four Metabolically Related Compounds by Means of Reversed-Phase High-Performance Liquid Chromatography with Electrochemical Detection,”J. Chromotography, 1981, 225:347-357.
Kitabgi et al., “Neurotensin Binding to Extraneural and Neural Receptors: Comparison with Biological Activity and Structure-Activity Relationships,”Mol. Pharmacol., 1980, 18:11-19.
Krstulovic, “Investigations of Catecholamine Metabolism Using High-Performance Liquid Chromatography,”J. Chromatogr., 1982, 229:1-34.
Lambert et al., “Anatomy and Mechanisms of Neurotensin-Dopamine Interactions in the Central Nervous System,”Ann. N.Y. Acad. Sci., 1995, 757:377-389.
Li et al., “Neurotensin peptides antagonistically regulate postynapic dopamine D2receptors in rat nucleus accumbens: a receptor binding and microdialyis study,”J. Neural Transm. [Gen Sect], 1995, 102:125-137.
McMahon et al., “Neurotensin analogs, Indications for use as potential antipsychotic compo
Boules Mona
Fredrickson Paul
Richelson Elliott
Andres Janet L.
Fish & Richardson P.C.
Mayo Foundation for Medical Education and Research
Tung Joyce
LandOfFree
Treating the effect of nicotine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating the effect of nicotine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating the effect of nicotine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711449